Tesamorelin Co / Evidence
Evidence
20 articles
EvidenceHow long does tesamorelin take to work?Phase 3 data show visceral fat drops start by week 14; full 26-week trials show ~15-18% VAT reduction. Here's the real timeline, by outcome.EvidenceTesamorelin: animal studies vs human clinical evidenceTesamorelin's approval rests on two phase 3 human trials, not animal data. See what's proven, what's extrapolated, and what's still off-label.EvidenceTesamorelin before and after claims: what the trials actually showTesamorelin trials show an 18% average visceral fat drop at 26 weeks in HIV lipodystrophy. Here's what before/after photos leave out, sourced to phase 3 data.EvidenceTesamorelin human studies: what the trials actually showTesamorelin's phase 3 trials cut visceral fat about 18% in HIV lipodystrophy. Here's what the human evidence covers, and where it stops.EvidenceTesamorelin mechanism of action: how it works in the bodyTesamorelin is a GHRH analogue that stimulates the pituitary to release GH in pulses. Here's the receptor biology behind its FDA-approved fat-reduction effect.EvidenceBest tesamorelin peptide: how to actually evaluate oneThere's no "best" tesamorelin brand, only FDA-approved Egrifta and compounded copies. Here's the real evidence, dosing and sourcing checklist before you buy.EvidenceCan women take tesamorelin peptide? what the evidence saysTesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy in adults, not sex-restricted. Here's what the trial data on women actually shows, and what's off-label.EvidenceDoes tesamorelin cause cancer? what the trial data showsTesamorelin's phase 3 trials found no increased cancer signal, but the label carries an IGF-1 caution and cancer patients were excluded. Here's the actual evidence.EvidenceHow long does it take for tesamorelin to work?Trial data shows visceral fat drops start by week 14, with full effect around 26 weeks. Here's the real timeline from the phase 3 tesamorelin studies.EvidenceHow to get tesamorelin: the legal, provider-reviewed routeTesamorelin (Egrifta) is FDA-approved by prescription only, for HIV lipodystrophy. Here's the real path to get it, on-label or off-label, and what to skip.EvidenceTesamorelin: the FDA-approved GHRH analogue, explainedTesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy visceral fat. Phase 3 data, dosing, off-label use, and safety facts, sourced and explained.EvidenceTesamorelin clinical trials: what the phase 3 data actually showsTesamorelin (Egrifta) cut visceral fat about 15-18% in phase 3 HIV trials vs placebo. Here's the trial evidence, what it covers, and what it doesn't.EvidenceTesamorelin in women: what the evidence actually showsEgrifta's phase 3 trials for HIV lipodystrophy enrolled few women. Here's the real female-specific evidence, dosing, and off-label questions answered.EvidenceTesamorelin nasal spray: is there a clinical trial?No approved tesamorelin nasal spray exists. FDA approval covers Egrifta injection only, backed by two phase 3 trials. Here's what the evidence actually shows.EvidenceTesamorelin before and after: what the trial data actually showPhase 3 trials found ~18% visceral fat reduction at 26 weeks with tesamorelin. Here's the real timeline, what changes, and what doesn't.EvidenceTesamorelin peptide stacks: what the evidence actually supportsTesamorelin is FDA-approved alone, for one indication. Stacking with IGF-1 LR3 or other peptides has no phase 3 data. Here's what's actually known.EvidenceTesamorelin results: what the clinical research actually showsTesamorelin cut visceral fat about 18% in phase 3 trials for HIV lipodystrophy. Here's the real evidence, what it doesn't show, and what's still off-label.EvidenceTesamorelin timeline: what to expect week by weekPhase 3 data show visceral fat drops start by week 14 and hold through 26-52 weeks. Here's the realistic tesamorelin timeline, dosed on real trial evidence.EvidenceWhat does tesamorelin actually do in the body?Tesamorelin is FDA-approved for HIV lipodystrophy: phase 3 trials show real visceral fat drops. Here's what it does, and doesn't do, backed by the data.EvidenceWhen to take tesamorelin: timing, cycle length, and dosingTesamorelin is dosed once daily at bedtime by subcutaneous injection. Here's what the phase 3 trials actually say about timing, cycles, and food.